Bipolar Research Today is a free monthly online journal that collates and summarizes the latest research about Bipolar, including details on bipolar disorder, symptoms, treatment, depression, medication.

Volume 7 (2010), Issue 4 (April)

1. Efficacy and acceptability of mood stabilisers in the treatment of acute bipolar depression: systematic review.
   Br J Psychiatry, 196: 266-73. [Abstract] [Full-text]
2. Genetics and intermediate phenotypes of the schizophrenia--bipolar disorder boundary.
   Neurosci Biobehav Rev, 34(6): 897-921. [Abstract] [Full-text]
3. Genetic association studies of glutamate, GABA and related genes in schizophrenia and bipolar disorder: a decade of advance.
   Neurosci Biobehav Rev, 34(6): 958-77. [Abstract] [Full-text]
4. Investigation of CNR1 and FAAH endocannabinoid gene polymorphisms in bipolar disorder and major depression.
   Pharmacol Res, 61(5): 400-4. [Abstract] [Full-text]
5. Mood disorders in laparoscopic sleeve gastrectomy patients: does it affect early weight loss?
   Surg Obes Relat Dis, 6(2): 191-6. [Abstract] [Full-text]
6. Consequences of receipt of a psychiatric diagnosis for completion of college.
   Psychiatr Serv, 61(4): 399-404. [Abstract] [Full-text]
7. Project among African-Americans to explore risks for schizophrenia (PAARTNERS): evidence for impairment and heritability of neurocognitive functioning in families of schizophrenia patients.
   Am J Psychiatry, 167(4): 459-72. [Abstract] [Full-text]
8. Borderline personality disorder and the misdiagnosis of bipolar disorder.
   J Psychiatr Res, 44(6): 405-8. [Abstract] [Full-text]
9. Aberrant REST-mediated transcriptional regulation in major depressive disorder.
   J Psychiatr Res, 44(6): 378-84. [Abstract] [Full-text]
10. Endoxifen is a new potent inhibitor of PKC: a potential therapeutic agent for bipolar disorder.
    Bioorg Med Chem Lett, 20(8): 2665-7. [Abstract] [Full-text]
11. Screening for bipolar disorder and finding borderline personality disorder.
    J Clin Psychiatry. [Abstract] [Full-text]
12. Neurocognitive functioning in patients with bipolar I disorder recently recovered from a first manic episode.
    J Clin Psychiatry. [Abstract] [Full-text]
13. Fine mapping of ZNF804A and genome-wide significant evidence for its involvement in schizophrenia and bipolar disorder.
    Mol Psychiatry. [Abstract] [Full-text]
14. Mitochondrial complex I activity and oxidative damage to mitochondrial proteins in the prefrontal cortex of patients with bipolar disorder.
    Arch Gen Psychiatry, 67(4): 360-8. [Abstract] [Full-text]
15. Longitudinal course of bipolar I disorder: duration of mood episodes.
    Arch Gen Psychiatry, 67(4): 339-47. [Abstract] [Full-text]
16. Rare copy number variants: a point of rarity in genetic risk for bipolar disorder and schizophrenia.
    Arch Gen Psychiatry, 67(4): 318-27. [Abstract] [Full-text]
17. Intracerebroventricular ouabain administration induces oxidative stress in the rat brain.
    Int J Dev Neurosci, 28(3): 233-7. [Abstract] [Full-text]
18. Olanzapine: in adolescents with schizophrenia or bipolar I disorder.
    CNS Drugs, 24(5): 443-52. [Abstract] [Full-text]
19. Neuropsychological functioning in early-onset first-episode psychosis: comparison of diagnostic subgroups.
    Eur Arch Psychiatry Clin Neurosci, 260(3): 225-33. [Abstract] [Full-text]
20. Correlates and antecedents of hospital admission for attempted suicide: a nationwide survey in Italy.
    Eur Arch Psychiatry Clin Neurosci, 260(3): 181-90. [Abstract] [Full-text]
21. Clinical and subthreshold panic disorder.
    Depress Anxiety, 27(4): 381-9. [Abstract] [Full-text]
22. 'A man can be destroyed but not defeated': Ernest Hemingway's near-death experience and declining health.
    Front Neurol Neurosci, 27: 174-206. [Abstract] [Full-text]
23. Brief interventions for patients presenting to the Psychiatric Emergency Service (PES) with major mental illnesses and at-risk drinking.
    Community Ment Health J, 46(2): 149-55. [Abstract] [Full-text]
24. A Canadian naturalistic study of a community-based cohort treated for bipolar disorder.
    BMC Psychiatry, 10: 24. [Abstract] [Full-text]
25. Functional polymorphism of matrix metalloproteinase-9 (MMP-9) gene in alcohol dependence: family and case control study.
    Brain Res, 1327: 103-6. [Abstract] [Full-text]
26. The effectiveness of multi-target agents in schizophrenia and mood disorders: Relevance of receptor signature to clinical action.
    Pharmacol Ther, 126(2): 173-85. [Abstract] [Full-text]
27. Proxy and patients ratings on quality of life in patients with schizophrenia and bipolar disorder in Korea.
    Qual Life Res, 19(4): 521-9. [Abstract] [Full-text]
28. Catechol-o-methyltransferase genotype and childhood trauma may interact to impact schizotypal personality traits.
    Behav Genet, 40(3): 415-23. [Abstract] [Full-text]
29. Age at onset and latency to treatment (duration of untreated illness) in patients with mood and anxiety disorders: a naturalistic study.
    Int Clin Psychopharmacol, 25(3): 172-9. [Abstract] [Full-text]
30. Altered expression of glutamate signaling, growth factor, and glia genes in the locus coeruleus of patients with major depression.
    Mol Psychiatry. [Abstract] [Full-text]
31. Genome-wide association study of bipolar I disorder in the Han Chinese population.
    Mol Psychiatry. [Abstract] [Full-text]
32. Psychopharmacology of aggression in children and adolescents with primary neuropsychiatric disorders: a review of current and potentially promising treatment options.
    Exp Clin Psychopharmacol, 18(2): 184-201. [Abstract] [Full-text]
33. Association between Serotonin-Related Polymorphisms in 5HT2A, TPH1, TPH2 Genes and Bipolar Disorder in Korean Population.
    Psychiatry Investig, 7(1): 60-7. [Abstract] [Full-text]
34. Differential association of circadian genes with mood disorders: CRY1 and NPAS2 are associated with unipolar major depression and CLOCK and VIP with bipolar disorder.
    Neuropsychopharmacology, 35(6): 1279-89. [Abstract] [Full-text]
35. Pro-apoptotic Par-4 and dopamine D2 receptor in temporal cortex in schizophrenia, bipolar disorder and major depression.
    Schizophr Res, 118(1): 292-9. [Abstract] [Full-text]
36. Is perseveration uniquely characteristic of schizophrenia?
    Schizophr Res, 118(1): 128-33. [Abstract] [Full-text]
37. Impact of obsessive-compulsive disorder comorbidity on the sociodemographic and clinical features of patients with bipolar disorder.
    Compr Psychiatry, 51(3): 293-7. [Abstract] [Full-text]
38. Apolipoprotein E genotype and Cognition in Bipolar Disorder.
    CNS Neurosci Ther. [Abstract] [Full-text]
39. White matter abnormalities in bipolar disorder: insights from diffusion tensor imaging studies.
    J Neural Transm, 117(5): 639-54. [Abstract] [Full-text]
40. Case reports of postmarketing adverse event experiences with olanzapine intramuscular treatment in patients with agitation.
    J Clin Psychiatry, 71(4): 433-41. [Abstract] [Full-text]
41. A randomized, placebo-controlled, multicenter study of divalproex sodium extended-release in the acute treatment of mania.
    J Clin Psychiatry, 71(4): 426-32. [Abstract] [Full-text]
42. Effect of Antipsychotic Medications on Glucose and Lipid Levels.
    J Clin Pharmacol. [Abstract] [Full-text]
43. Verbal and Visual Memory Impairments Among Young Offspring and Healthy Adult Relatives of Patients With Schizophrenia and Bipolar Disorder: Selective Generational Patterns Indicate Different Developmental Trajectories.
    Schizophr Bull. [Abstract] [Full-text]
44. Antidepressant discontinuation in bipolar depression: a Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD) randomized clinical trial of long-term effectiveness and safety.
    J Clin Psychiatry, 71(4): 372-80. [Abstract] [Full-text]
45. Sleep architecture as correlate and predictor of symptoms and impairment in inter-episode bipolar disorder: taking on the challenge of medication effects.
    J Sleep Res. [Abstract] [Full-text]
46. Behavioral analyses of transgenic mice harboring bipolar disorder candidate genes, IMPA1 and IMPA2.
    Neurosci Res, 67(1): 86-94. [Abstract] [Full-text]
47. Affective temperaments across the bipolar-unipolar spectrum: examination of the TEMPS-A in 927 patients and controls.
    J Affect Disord, 123(1): 42-51. [Abstract] [Full-text]
48. Effect of ethacrynic acid on the sodium- and potassium-activated adenosine triphosphatase activity and expression in Old Order Amish bipolar individuals.
    J Affect Disord, 123(1): 303-7. [Abstract] [Full-text]
49. The impact of staging bipolar disorder on treatment outcome of family psychoeducation.
    J Affect Disord, 123(1): 81-6. [Abstract] [Full-text]
50. Psychoeducation for patients with bipolar disorder receiving lithium: short and long term impact on locus of control and knowledge about lithium.
    J Affect Disord, 123(1): 299-302. [Abstract] [Full-text]
51. Suicidal behaviour in a French Cohort of major depressive patients: characteristics of attempters and nonattempters.
    J Affect Disord, 123(1): 87-94. [Abstract] [Full-text]
52. Gray matter reduction of the superior temporal gyrus in patients with established bipolar I disorder.
    J Affect Disord, 123(1): 276-82. [Abstract] [Full-text]
53. Distinct neuronal oscillatory responses between patients with bipolar and unipolar disorders: a magnetoencephalographic study.
    J Affect Disord, 123(1): 270-5. [Abstract] [Full-text]
54. Theory of mind impairments in euthymic bipolar patients.
    J Affect Disord, 123(1): 264-9. [Abstract] [Full-text]
55. The impact of comorbid posttraumatic stress disorder on bipolar disorder patients.
    J Affect Disord, 123(1): 71-6. [Abstract] [Full-text]
56. Late-life bipolar depression due to the soft form of bipolar disorder compared to unipolar depression: an inpatient chart review study.
    J Affect Disord, 123(1): 64-70. [Abstract] [Full-text]
57. Impaired theory of mind performance in patients with recurrent bipolar disorder: Moderating effect of cognitive load.
    Psychiatry Res, 177(1): 261-2. [Abstract] [Full-text]
58. Evidence for gamma inhibition deficits in the dorsolateral prefrontal cortex of patients with schizophrenia.
    Brain, 133: 1505-14. [Abstract] [Full-text]
59. Increased plasma levels of brain-derived neurotrophic factor in patients with long-term bipolar disorder.
    Neurosci Lett, 475(2): 95-8. [Abstract] [Full-text]
60. The expression of HMGA1a is increased in lymphoblastoid cell lines from schizophrenia patients.
    Neurochem Int, 56(6): 736-9. [Abstract] [Full-text]
61. Correlates of recovery of social functioning in types I and II bipolar disorder patients.
    Psychiatry Res, 177(1): 131-4. [Abstract] [Full-text]
62. Pharmacological response in juvenile bipolar disorder subtypes: A naturalistic retrospective examination.
    Psychiatry Res, 177(1): 192-8. [Abstract] [Full-text]
63. Psychiatric health care provider attitudes towards implantable medication.
    Psychiatry Res, 177(1): 167-71. [Abstract] [Full-text]
64. Smoking outcome by psychiatric history after behavioral and varenicline treatment.
    J Subst Abuse Treat, 38(4): 394-402. [Abstract] [Full-text]
65. Lifetime manic-hypomanic symptoms in post-traumatic stress disorder: Relationship with the 18 kDa mitochondrial translocator protein density.
    Psychiatry Res, 177(1): 139-43. [Abstract] [Full-text]
66. Therapeutic itineraries of 'depressed' women in Greece: power relationships and agency in therapeutic pluralism.
    Anthropol Med, 17(1): 41-57. [Abstract] [Full-text]
67. New therapeutic targets for mood disorders.
    ScientificWorldJournal, 10: 713-26. [Abstract] [Full-text]
68. A prospective open-label trial of lamotrigine monotherapy in children and adolescents with bipolar disorder.
    CNS Neurosci Ther, 16(2): 91-102. [Abstract] [Full-text]
69. Moderators, mediators, and other predictors of risperidone response in children with autistic disorder and irritability.
    J Child Adolesc Psychopharmacol, 20(2): 83-93. [Abstract] [Full-text]
70. Pharmacology and efficacy of asenapine for manic and mixed states in adults with bipolar disorder.
    Expert Rev Neurother, 10(5): 645-9. [Abstract] [Full-text]
71. The process of recovery from bipolar I disorder: a qualitative analysis of personal accounts in relation to an integrative cognitive model.
    Br J Clin Psychol, 49: 193-215. [Abstract] [Full-text]
72. Autobiographical memory specificity, depression, and trauma in bipolar disorder.
    Br J Clin Psychol, 49: 217-33. [Abstract] [Full-text]
73. The impact of mood disorders and their treatment on the pregnant woman, the fetus, and the infant.
    Curr Psychiatry Rep, 12(2): 96-103. [Abstract] [Full-text]
74. Do treatment and illness beliefs influence adherence to medication in patients with bipolar affective disorder? A preliminary cross-sectional study.
    Eur Psychiatry, 25(4): 216-9. [Abstract] [Full-text]
75. In search of optimal lithium levels and olanzapine doses in the long-term treatment of bipolar I disorder. A post-hoc analysis of the maintenance study by Tohen et al. 2005.
    Eur Psychiatry. [Abstract] [Full-text]
76. Lithium in chronic renal failure: a case report.
    Gen Hosp Psychiatry, 32(3): 341.e3-5. [Abstract] [Full-text]

© 2004-2013 Bipolar Research Today. All Rights Reserved.